Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06409169 · ClinicalTrials.gov registry record · NA
DBS TaT in Peer-assisted Telemedicine for Hepatitis C
A NA study of Hepatitis C, sponsored by Oregon Health and Science University.
- Recruiting
- Registry status
- NA
- Development phase
- 141
- Enrollment target
- 1
- Study location
NCT06409169: Recruiting NA study of Hepatitis C, sponsored by Oregon Health and Science University.
NCT06409169 is a NA study of Hepatitis C that is actively recruiting participants, run by Oregon Health and Science University. The registered enrollment target is 141 participants, below the 1,889-participant average among 106 other Hepatitis C trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06409169, a NA study of Hepatitis C, is actively recruiting participants, sponsored by Oregon Health and Science University.
- RECRUITING
- Registry status
- NA
- Development phase
- 141 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to compare the rate of treatment initiation achieved by peer-assisted telemedicine contingent on phlebotomy (usual care) versus that achieved with a new protocol, called Dried Blood Spot Test and Treat (DBS TaT). DBS TaT includes DBS testing to diagnose hepatitis C (HCV), utilizes a novel clinical decision aid that identifies patients who are low risk for hepatic (liver) fibrosis, and directs those patients to HCV treatment initiation prior to routine hepatic fibrosis assessment. The investigators hypothesize that DBS TaT will increase the rate of HCV treatment initiation compared to peer-assisted telemedicine contingent on phlebotomy (usual care).
Primary Outcome
Rate of hepatitis C (HCV) treatment initiation in sites utilizing DBS TaT versus sites utilizing usual care.
Conditions Studied
Interventions
- OTHER Usual Care
- OTHER DBS TaT
Study Locations (1)
Oregon
- Oregon Health & Science University - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 141 participants |
| Start Date | 2025-01-22 |
| Est. Completion | 2026-05 |
| Phase | NA |
What NCT06409169 shows while recruiting
NCT06409169 is an interventional study that assigns participants to a tested intervention. The registered 141 participants enrollment target is mid-sized for trials with a published cap, below the 1,889-participant average among 106 other Hepatitis C trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Hepatitis C appearing as the primary indexed condition, and to 2 interventions - of which Usual Care is the first listed.
NCT06409169 reports a single indexed study location in Oregon.
Frequently Asked Questions
What is clinical trial NCT06409169 about?
NCT06409169 is a clinical study titled "DBS TaT in Peer-assisted Telemedicine for Hepatitis C". The purpose of this study is to compare the rate of treatment initiation achieved by peer-assisted telemedicine contingent on phlebotomy (usual care) versus that achieved with a new protocol, called Dried Blood Spot Test and Treat (DBS TaT). DBS TaT includes DBS testing to diagnose hepatitis C (HCV)...
What is the current status of trial NCT06409169?
This trial is currently recruiting. It is a NA study. The enrollment target is 141 participants. The study started on 2025-01-22. Estimated completion is 2026-05.
What conditions does trial NCT06409169 study?
This clinical trial studies the following conditions: Hepatitis C.
What interventions are being tested in trial NCT06409169?
The interventions under investigation include: Usual Care (OTHER), DBS TaT (OTHER).
Who is sponsoring clinical trial NCT06409169?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06409169 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatitis C
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06409169's enrollment target sits among peer trials
141 48th of 106 higher than 59 of 106 other Hepatitis C trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hepatitis C trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Project I Test: Implementing HIV Testing in Opioid Treatment Programs
RECRUITING · NA
-
Partner Navigation Intervention for Hepatitis C Treatment Among Young People Who Inject Drugs
RECRUITING · NA
-
HCV Tappt Adherence Study
RECRUITING · NA
-
Use of a Patient-Centered Electronic App to Increase ED Patient's Knowledge on HCV to Improve the HCV Care Continuum
RECRUITING · NA
-
Buprenorphine Integration Research and Community Health
ACTIVE NOT RECRUITING · NA
-
Tele-Harm Reduction
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03042962 · 141 participants
Brain Networks in Dystonia
- NCT04378439 · 141 participants · NA
Appalachian Partnership to Reduce Disparities (Aim 2)
- NCT04775485 · 141 participants · Phase 2
A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors
- NCT05040360 · 141 participants · Phase 2
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI